Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of WD-890 tablets in active systemic lupus erythematosus
CTR20263330Phase 2Active
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing WD-890 plus stable background therapy with Placebo plus stable background therapy (2 arms). Primary endpoint: SRI-4 response rate at Week 32. Started Aug 2026; status: active.
02
Drugs
WD-890
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20263330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263330.